文献速递治疗药物监测与药物基因组学特殊人群用药

全基因NGS测序提升他莫昔芬治疗患者CYP2D6基因型-表型一致性

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?
PubMed 文献 · Clin Pharmacol Ther · 2026-06-18

研究从68例他莫昔芬治疗患者中选取靶向基因分型与药代动力学表型不一致者,采用全基因NGS测序。全基因测序在41%患者中修正基因型、19%改变代谢者状态;排除初始检测漏检的常见等位基因后,二倍体型判定改善23.5%、代谢者分类改善7.4%,主要来自结构变异的检出。

要点

  • 靶向CYP2D6分型漏检常见及结构变异等位基因,可造成基因型-表型不一致
  • 全基因NGS在预选的不一致人群中修正基因型41%、改变代谢者状态19%
  • 排除初始检测漏检因素后二倍体型判定仍改善23.5%,主要来自结构变异检出

核心结论

  • 在预先按基因型-表型不一致选出的他莫昔芬治疗患者队列中,全面CYP2D6测序提高了基因谱分析准确性。
  • 罕见变异解读仍是药物基因组学指导治疗药物监测的剩余挑战。

研究设计与样本

  • 从接受他莫昔芬治疗的患者队列中,依据靶向CYP2D6基因分型与药代动力学表型不一致,选取68例个体。
  • 采用全基因下一代测序(NGS),配合自建 panel 与生物信息学流程进行分析。

主要发现

  • 全基因CYP2D6测序在41%患者中修正基因型,在19%患者中改变代谢者状态,主要因检出初始靶向检测漏检的常见等位基因。
  • 排除上述差异来源后,测序使23.5%患者二倍体型判定改善、7.4%代谢者状态分类改善,主要来自结构变异检出。
  • 另检出1例罕见无功能等位基因CYP2D6*62及CYP2D6*22、*23、*28、p.Ala165Gly、p.Pro264Thr等罕见或意义不明变异,并以适应化 in silico 预测策略结合表型与已发表体外数据进行评估。

临床怎么用

  • 对靶向CYP2D6分型与临床表型不符的他莫昔芬治疗患者,可考虑全基因NGS以发现漏检等位基因与结构变异。
  • 解读NGS结果时须重视罕见及意义不明变异,需结合表型与体外数据综合判断。

局限性

  • 研究为预选的不一致队列,样本仅68例,结果外推需谨慎。
  • 罕见变异的功能解读仍存在挑战,部分变异意义尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CYP2D6 metabolizes about 20% of commonly used drugs, including tamoxifen, a major hormone therapy for breast cancer. Although the relationship between tamoxifen pharmacokinetics and CYP2D6 genotype has been demonstrated, residual variability in drug exposure remains unexplained. Given the high genetic polymorphism of CYP2D6, including copy number variations and hybrid genes, targeted genotyping may fail to capture rare or complex alleles. To explore this limitation, 68 individuals from a cohort of tamoxifen-treated patients were selected based on discordance between CYP2D6 genotype determined by a targeted approach and phenotype assessed from pharmacokinetic data, and were analyzed using full-gene next-generation sequencing with in-house panel and bioinformatics pipeline. Full CYP2D6 gene sequencing refined genotypes in 41% of patients, and changed metabolizer status in 19%, mainly by detecting common alleles missed by the initial targeted assay. After removing these sources of discrepancy, sequencing improved diplotype assignment in 23.5% and metabolizer status classification in 7.4% of patients, largely driven by the detection of structural variants, with an additional contribution from the rare nonfunctional CYP2D6*62 allele, identified in one patient. In addition, several rare variants or variants of uncertain significance (including CYP2D6*22, *23, *28, p.Ala165Gly. and p.Pro264Thr) were identified and further evaluated using adapted in silico prediction strategies, compared with patients' phenotypes and published in vitro data. Comprehensive CYP2D6 sequencing improved gene profiling accuracy in our preselected cohort, while highlighting the remaining challenges of rare variant interpretation in pharmacogenetics-guided therapeutic drug monitoring.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Petit J, Plenecassagnes J, Brice A, et al. Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients? Clin Pharmacol Ther. 2026. PMID: 42312965. doi:10.1002/cpt.70360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。